OVERVIEW

Innovations in the Management of Hemolytic Disease of the Fetus and Newborn (HDFN): The Role of the Neonatal Fc Receptor (FcRn) Pathway is organized by Omnia Education.

Release Date: 08/08/2024
Expiration Date: 08/08/2025

Description:
Hemolytic disease of the fetus and newborn (HDFN) is an alloimmune disorder between the mother and fetus, one with significant risk for dire health consequences for both. Fortunately, a better understanding of the neonatal Fc receptor (FcRn) pathway along with the emergence of an inhibitor of this pathway has brought with it an opportunity to greatly reduce the potential harm associated with HDFN. Join us as Drs. Kenneth Moise and Kara Markham discuss the pathophysiology of HDFN and present key clinical data that may change the landscape of medical intervention for HDFN.

Learning Objectives
After participating in this educational activity, participants should be better able to:

Describe the pathophysiologic processes associated with hemolytic disease of the fetus and newborn (HDFN)
Identify current treatment approaches for HDFN
Explain the role of the neonatal Fc receptor (FcRn) pathway as a therapeutic target in the management of HDFN
Discuss clinical data supporting a potential role for nipocalimab in the management of HDFN

ACCREDITATION & CREDITS

Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until August 8th, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

0.25 AMA PRA Category 1 Credit™

0.25 Contact Hour

0.25 CME

TARGET AUDIENCE

PhysicianNursingPhysician AssistantObstetrics and Gynecology PhysiciansNeonatologistPediatriciansNursesHematologistObstetriciansNurse PractitionersGynaecologistImmunologists